A citation-based method for searching scientific literature

David Moher, Alessandro Liberati, Jennifer Tetzlaff, Douglas G Altman. BMJ 2009
Times Cited: 11230







List of co-cited articles
68 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.
Julian P T Higgins, Douglas G Altman, Peter C Gøtzsche, Peter Jüni, David Moher, Andrew D Oxman, Jelena Savovic, Kenneth F Schulz, Laura Weeks, Jonathan A C Sterne. BMJ 2011
14

Measuring inconsistency in meta-analyses.
Julian P T Higgins, Simon G Thompson, Jonathan J Deeks, Douglas G Altman. BMJ 2003
11

Bias in meta-analysis detected by a simple, graphical test.
M Egger, G Davey Smith, M Schneider, C Minder. BMJ 1997
10


Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.
D F Stroup, J A Berlin, S C Morton, I Olkin, G D Williamson, D Rennie, D Moher, B J Becker, T A Sipe, S B Thacker. JAMA 2000
6


AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both.
Beverley J Shea, Barnaby C Reeves, George Wells, Micere Thuku, Candyce Hamel, Julian Moran, David Moher, Peter Tugwell, Vivian Welch, Elizabeth Kristjansson,[...]. BMJ 2017
6

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.
Alessandro Liberati, Douglas G Altman, Jennifer Tetzlaff, Cynthia Mulrow, Peter C Gøtzsche, John P A Ioannidis, Mike Clarke, P J Devereaux, Jos Kleijnen, David Moher. BMJ 2009
6

RoB 2: a revised tool for assessing risk of bias in randomised trials.
Jonathan A C Sterne, Jelena Savović, Matthew J Page, Roy G Elbers, Natalie S Blencowe, Isabelle Boutron, Christopher J Cates, Hung-Yuan Cheng, Mark S Corbett, Sandra M Eldridge,[...]. BMJ 2019
6

Quantifying heterogeneity in a meta-analysis.
Julian P T Higgins, Simon G Thompson. Stat Med 2002
5

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.
Gordon H Guyatt, Andrew D Oxman, Gunn E Vist, Regina Kunz, Yngve Falck-Ytter, Pablo Alonso-Coello, Holger J Schünemann. BMJ 2008
5

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.
Jonathan Ac Sterne, Miguel A Hernán, Barnaby C Reeves, Jelena Savović, Nancy D Berkman, Meera Viswanathan, David Henry, Douglas G Altman, Mohammed T Ansari, Isabelle Boutron,[...]. BMJ 2016
5

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
David Moher, Alessandro Liberati, Jennifer Tetzlaff, Douglas G Altman. PLoS Med 2009
5

Meta-analysis in clinical trials.
R DerSimonian, N Laird. Control Clin Trials 1986
4

The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies.
Andra Morrison, Julie Polisena, Don Husereau, Kristen Moulton, Michelle Clark, Michelle Fiander, Monika Mierzwinski-Urban, Tammy Clifford, Brian Hutton, Danielle Rabb. Int J Technol Assess Health Care 2012
472
3



GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology.
Gordon H Guyatt, Andrew D Oxman, Holger J Schünemann, Peter Tugwell, Andre Knottnerus. J Clin Epidemiol 2011
3

A basic introduction to fixed-effect and random-effects models for meta-analysis.
Michael Borenstein, Larry V Hedges, Julian P T Higgins, Hannah R Rothstein. Res Synth Methods 2010
3

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.
Alessandro Liberati, Douglas G Altman, Jennifer Tetzlaff, Cynthia Mulrow, Peter C Gøtzsche, John P A Ioannidis, Mike Clarke, P J Devereaux, Jos Kleijnen, David Moher. J Clin Epidemiol 2009
3

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables.
Gordon Guyatt, Andrew D Oxman, Elie A Akl, Regina Kunz, Gunn Vist, Jan Brozek, Susan Norris, Yngve Falck-Ytter, Paul Glasziou, Hans DeBeer,[...]. J Clin Epidemiol 2011
3

Assessing the quality of reports of randomized clinical trials: is blinding necessary?
A R Jadad, R A Moore, D Carroll, C Jenkinson, D J Reynolds, D J Gavaghan, H J McQuay. Control Clin Trials 1996
2


Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis.
Zhaohai Zheng, Fang Peng, Buyun Xu, Jingjing Zhao, Huahua Liu, Jiahao Peng, Qingsong Li, Chongfu Jiang, Yan Zhou, Shuqing Liu,[...]. J Infect 2020
780
2

Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes.
Aidin Rawshani, Araz Rawshani, Stefan Franzén, Björn Eliasson, Ann-Marie Svensson, Mervete Miftaraj, Darren K McGuire, Naveed Sattar, Annika Rosengren, Soffia Gudbjörnsdottir. N Engl J Med 2017
460
2

Venous thromboembolism in critically Ill patients with COVID-19: Results of a screening study for deep vein thrombosis.
Alban Longchamp, Justine Longchamp, Sara Manzocchi-Besson, Livia Whiting, Claude Haller, Séverin Jeanneret, Manoelle Godio, Juan Jose Garcia Martinez, Thierry Bonjour, Mary Caillat,[...]. Res Pract Thromb Haemost 2020
56
3

Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study.
Christian Karagiannidis, Carina Mostert, Corinna Hentschker, Thomas Voshaar, Jürgen Malzahn, Gerhard Schillinger, Jürgen Klauber, Uwe Janssens, Gernot Marx, Steffen Weber-Carstens,[...]. Lancet Respir Med 2020
256
2

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis.
F A Klok, M J H A Kruip, N J M van der Meer, M S Arbous, D Gommers, K M Kant, F H J Kaptein, J van Paassen, M A M Stals, M V Huisman,[...]. Thromb Res 2020
801
2

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients.
Jean-François Llitjos, Maxime Leclerc, Camille Chochois, Jean-Michel Monsallier, Michel Ramakers, Malika Auvray, Karim Merouani. J Thromb Haemost 2020
563
2

Dexamethasone in Hospitalized Patients with Covid-19.
Peter Horby, Wei Shen Lim, Jonathan R Emberson, Marion Mafham, Jennifer L Bell, Louise Linsell, Natalie Staplin, Christopher Brightling, Andrew Ustianowski, Einas Elmahi,[...]. N Engl J Med 2021
2


Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.
Safiya Richardson, Jamie S Hirsch, Mangala Narasimhan, James M Crawford, Thomas McGinn, Karina W Davidson, Douglas P Barnaby, Lance B Becker, John D Chelico, Stuart L Cohen,[...]. JAMA 2020
2

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study.
Julie Helms, Charles Tacquard, François Severac, Ian Leonard-Lorant, Mickaël Ohana, Xavier Delabranche, Hamid Merdji, Raphaël Clere-Jehl, Malika Schenck, Florence Fagot Gandet,[...]. Intensive Care Med 2020
2

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia.
Songping Cui, Shuo Chen, Xiunan Li, Shi Liu, Feng Wang. J Thromb Haemost 2020
844
2

Incidence of thrombotic complications in critically ill ICU patients with COVID-19.
F A Klok, M J H A Kruip, N J M van der Meer, M S Arbous, D A M P J Gommers, K M Kant, F H J Kaptein, J van Paassen, M A M Stals, M V Huisman,[...]. Thromb Res 2020
2

Characteristics and Outcomes of Coronavirus Disease Patients under Nonsurge Conditions, Northern California, USA, March-April 2020.
Jessica Ferguson, Joelle I Rosser, Orlando Quintero, Jake Scott, Aruna Subramanian, Mohammad Gumma, Angela Rogers, Shanthi Kappagoda. Emerg Infect Dis 2020
45
4

Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease 2019.
Thomas K Maatman, Farid Jalali, Cyrus Feizpour, Anthony Douglas, Sean P McGuire, Gabriel Kinnaman, Jennifer L Hartwell, Benjamin T Maatman, Rolf P Kreutz, Rajat Kapoor,[...]. Crit Care Med 2020
85
2

Meta-analysis of prevalence.
Jan J Barendregt, Suhail A Doi, Yong Yi Lee, Rosana E Norman, Theo Vos. J Epidemiol Community Health 2013
789
2

Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom.
W Thomas, J Varley, A Johnston, E Symington, M Robinson, K Sheares, A Lavinio, M Besser. Thromb Res 2020
112
2


Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies.
Konstantinos K Tsilidis, John C Kasimis, David S Lopez, Evangelia E Ntzani, John P A Ioannidis. BMJ 2015
327
2

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Fei Zhou, Ting Yu, Ronghui Du, Guohui Fan, Ying Liu, Zhibo Liu, Jie Xiang, Yeming Wang, Bin Song, Xiaoying Gu,[...]. Lancet 2020
2



Plea for routinely presenting prediction intervals in meta-analysis.
Joanna IntHout, John P A Ioannidis, Maroeska M Rovers, Jelle J Goeman. BMJ Open 2016
387
2

The GRADE Working Group clarifies the construct of certainty of evidence.
Monica Hultcrantz, David Rind, Elie A Akl, Shaun Treweek, Reem A Mustafa, Alfonso Iorio, Brian S Alper, Joerg J Meerpohl, M Hassan Murad, Mohammed T Ansari,[...]. J Clin Epidemiol 2017
170
2


Estimating the mean and variance from the median, range, and the size of a sample.
Stela Pudar Hozo, Benjamin Djulbegovic, Iztok Hozo. BMC Med Res Methodol 2005
2




Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.